Remission of treatment-resistant depression with tardive akathisia with electroconvulsive therapy

BMJ Case Rep. 2019 Sep 18;12(9):e229714. doi: 10.1136/bcr-2019-229714.

Abstract

This report presents a case of drug-induced severe tardive akathisia developing after the combination of a selective serotonin reuptake inhibitor and an antipsychotic, in a woman with severe major depression. The trial and combination of multiple medications is common practice in treatment-resistant patients with depression. With the increase in the prevalence of treatment-resistant depression, adverse effects of medication such as tardive akathisia are becoming more common. Tardive akathisia persists even after the withdrawal of the causative agent and is very challenging to treat. The patient did not respond to any standard medications indicated for drug-induced akathisia. As a result, the patient became suicidal and extremely distressed with all treatment options exhausted. Guidelines on the management of drug-induced tardive akathisia are non-existent. This reflects the importance of this case study, which reveals the complete remission of both tardive akathisia and all the patient's depressive symptoms after electroconvulsive therapy . This report provides evidence of an established treatment intervention used in a new situation.

Keywords: depressive disorder; drug interactions; movement disorders (other than parkinsons); psychiatry (drugs and medicines); unwanted effects/adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Akathisia, Drug-Induced / complications
  • Akathisia, Drug-Induced / therapy*
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Depressive Disorder, Treatment-Resistant / therapy*
  • Diagnosis, Differential
  • Electroconvulsive Therapy / methods*
  • Female
  • Humans
  • Middle Aged
  • Remission Induction
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors